Latest news

• Roche launches digital PCR system to identify ultra-rare and emerging disease mutations

  Also in August, Roche announced a collaboration with Cend therapeutics to evaluate CEND-1 in combination with Roche’s Tecentriq (atezolizumab), and standard-of-care chemotherapy in patients with metastatic pancreatic ... ductal adenocarcinoma (mPDAC).

• Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy

  Pancreatic cancer is the third leading cause of cancer-related deaths, with over 430, 000 deaths each year. ... Roche and Cend Therapeutics (Cend) will collaborate to evaluate CEND-1 in combination with Roche’s Tecentriq (atezolizumab), and

• Gilead to pay $745m for three oncology programmes from Arcus Biosciences

  inhibitor in a phase 1 study in metastatic pancreatic ductal adenocarcinoma. ... deliver benefit to patients with some of the most difficult to treat cancers, including pancreatic, lung, colon and prostate.”.

• Merus makes case for bispecific antibody in specific cancer gene fusion

  assessment. The three patients are currently remaining on treatment. The data also showed that the experimental therapy worked across cancer types – patient one and two had pancreatic ductal adenocarcinoma, with the ... It is notable that two of the